2.43
0.07 (2.75%)
| Previous Close | 2.37 |
| Open | 2.36 |
| Volume | 1,568,765 |
| Avg. Volume (3M) | 2,497,546 |
| Market Cap | 237,213,344 |
| Price / Sales | 4.39 |
| Price / Book | 17.38 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -758.05% |
| Diluted EPS (TTM) | -3.04 |
| Quarterly Revenue Growth (YOY) | 310.40% |
| Total Debt/Equity (MRQ) | 49.88% |
| Current Ratio (MRQ) | 3.08 |
| Operating Cash Flow (TTM) | -208.21 M |
| Levered Free Cash Flow (TTM) | -103.52 M |
| Return on Assets (TTM) | -36.80% |
| Return on Equity (TTM) | -140.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Editas Medicine, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.33% |
| % Held by Institutions | 57.56% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |